Administration of the HDAC1/2 inhibitor valproic acid (VPA) from P2-23 caused similar deficits in myelination and behavioral abnormalities seen in rats exposed to MS, whereas injecting the WNT antagonist XAV939 during the first 3 weeks of life reversed the myelination and behavioral abnormalities seen in MS. The gene discussed is HDAC1; the disease is myeloid sarcoma.